Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LY 3410738

Next Previous
Drug Profile

LY 3410738

Alternative Names: LY-3410738

Latest Information Update: 23 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Loxo Oncology
  • Class Antineoplastics
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors; Isocitrate dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies; Solid tumours

Most Recent Events

  • 08 Aug 2023 Discontinued - Phase-I for Haematological malignancies (Late-stage disease, Second-line therapy or greater) in USA, Taiwan, Spain, Singapore, South Korea, Israel, Germany, France, Canada, Belgium, Australia (PO) (Eli Lilly and Company pipeline, August 2023)
  • 08 Aug 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA, Australia, France, Hong Kong, Japan, South Korea, Singapore, Singapore, Spain, Spain, Taiwan (PO) (Eli Lilly and Company pipeline, August 2023)
  • 14 Apr 2023 Efficacy and adverse events data from a phase I trial in Haematological malignancies (Late-stage disease, Second-line therapy or greater) presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top